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This study aimed to evaluate the feasibility and efficacy of neoadjuvant chemoradiotherapy intensified with irinotecan in patients with
locally advanced rectal cancer. Eligible patients had nonmetastatic disease at a locally advanced stage that made R0 resection and
sphincter preservation uncertain. They received preoperative radiation over 6 weeks to 45Gy and boost of 5.4Gy and concurrent
continuous infusion 5-fluorouracil 250mgm
 2day
 1 and weekly irinotecan 40mgm
 2. In all, 37 patients entered the study. T stage at
baseline as determined by ultrasound was T2/T3/T4 in 2/19/16 patients; 31 patients had lymph node involvement. The predominant
toxicity was diarrhoea (grade 3/4 in 10/2 patients). Haematologic toxicity and surgical complications were moderate. Among 36
patients undergoing surgery, 32 (89%) had R0 resection and 23 (64%) sphincter preservation. Pathologic complete response (pCR)
was achieved in eight (22%) of 36 patients, and 10 patients (28%) had only microscopic residual disease. At 4 years, overall survival
was 66%, disease-free survival 73%, local relapse rate 7%, and distant failure rate 24%. Extent of resection and postoperative nodal
status were significant predictors of overall and disease-free survival. Intensified neoadjuvant chemoradiotherapy with irinotecan can
be safely administered and results in a high pCR rate.
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It is of critical prognostic significance in rectal cancer whether or
not a resection of the tumour with clear margins (R0) can be
achieved (Hermanek and Wittekind, 1994). On the other hand,
maintenance of foecal continence is of crucial importance for the
patients’ quality of life. Even if state-of-the art surgical techniques
are used, often both of these aims cannot be accomplished in
locally advanced tumours, particularly if they are located in
the lower third of the rectum. Several phase II studies of
5-fluorouracil-based preoperative chemoradiotherapy for locally
advanced rectal cancer have reported R0 resection rates of 60–85%
(Chan et al, 1993; Minsky et al, 1993; Keilholz et al, 1995; Videtic
et al, 1998; Ku ¨chenmeister et al, 2000; Ro ¨del et al, 2000) including
pathologic complete response (pCR) rates of 5–20%. Even in low
rectal tumours, sphincter-preserving surgery was possible after
preoperative chemoradiotherapy in 27–86% of the patients (Grann
et al, 1997; Hyams et al, 1997; Maghfoor et al, 1997; Ku ¨chenmeister
et al, 2000). Moreover, randomised trials have shown that
neoadjuvant chemoradiotherapy improves local control compared
with postoperative chemoradiation in primary resectable tumours
(Roh et al, 2001; Sauer et al, 2004). The probability of distant
metastasis, however, is not reduced. In addition to the well-
established agent 5-fluorouracil, new agents such as irinotecan or
oxaliplatin have proven effective in the treatment of metastatic
colorectal cancer. Therefore, the present phase II study was aimed
to determine the feasibility and local efficacy of an intensified
neoadjuvant treatment approach using concurrent radiation and
chemotherapy with 5-fluorouracil and irinotecan in patients with
locally far advanced rectal cancer.
PATIENTS AND METHODS
Patient eligibility
Male and female patients with histologically confirmed adenocar-
cinoma of the rectum were prospectively enrolled in the study if
they presented with nonmetastatic disease at a locally advanced
stage that made R0 resection and sphincter preservation uncertain.
Other eligibility criteria included measurable disease (at least one
bidimensionally measurable tumour lesion), WHO performance
status p2, adequate haematologic, hepatic and renal function, and
life expectancy of at least 3 months. Pregnant or lactating women,
patients with unresolved bowel obstruction or ileus/subileus, and
those with a history of chronic diarrhea were ineligible for study
entry. All patients underwent baseline examination and staging
within 2–4 weeks prior to the start of chemoradiotherapy,
including history and physical examination, complete blood count,
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sserum chemistry profile, chest X-ray, rectoscopy or sigmoido-
scopy, endoluminal ultrasound, abdominal ultrasound, and
computed tomography (CT) of the abdomen and pelvis. Inclusion
of approximately 35 patients was planned. The study was approved
by the local ethics committee, and written informed consent was
obtained from all patients.
Treatment
Computed tomography-assisted three-dimensional planning of
radiation therapy was employed. The patients underwent CT with
5mm slices, contrast administration to bladder, rectum and small
intestine, and endoscopic clipping (Riepl et al, 2000) of the upper
and lower borders of the tumour performed immediately prior to
planning. Radiation therapy was given with photons from a linear
accelerator with energy 46MV. The target volume comprised the
areas at risk including the presacral space along the posterior
bladder or vaginal wall, respectively, and the common iliac lymph
nodes until and including the fifth lumbar vertebral body.
Radiotherapy was delivered with three or four fields using an
isocentric technique with individually collimated field portals.
Daily fractions of 1.8Gy (isodose 90% of the maximum dose) were
given on 5 days a week over 5 weeks to a total dose of 45Gy
(isodose 90%, corresponding to 47.5–48Gy as calculated accord-
ing to the International Commission on Radiation Units and
Measurements (ICRU) reference point approach). An additional
low-volume boost of 5.4Gy (5.8Gy by ICRU reference point
approach) was given in three fractions on days 1–3 of week 6 of
treatment to the site of the primary tumour after previous contrast
radiography of the small intestine.
Radiation was administered with concurrent chemotherapy that
consisted of 5-fluorouracil given by continuous infusion via an
implantable port system at a daily dose of 250mgm
 2 throughout
the entire treatment period (days 1–43). In addition, irinotecan
was administered once weekly at 40mgm
 2 by 90-min infusion
immediately prior to the first weekly fraction of radiation.
Premedication with atropin 0.25mg subcutaneously was recom-
mended to prevent irinotecan-associated acute cholinergic
syndrome. Irinotecan doses were omitted if leucocyte or platelet
nadir values were less than 2000ml
 1 or o75000ml
 1, respectively,
or if grade 4 toxicity occurred.
Restaging and surgery using total mesorectal excision was to be
performed within 4–6 weeks after completion of chemoradio-
therapy. Following surgery, patients usually received adjuvant
chemotherapy with 5-FU with or without folinic acid according to
the recommendations of the German Cancer Society (DKG).
Data evaluation
The deadline for data evaluation was December 31, 2003. Statistical
analysis including survival analysis according to Kaplan–Meier
was performed with the SPSS software package. Survival was
calculated from the date of histologic verification of diagnosis to
the patient’s death or the date of last follow-up. Progression-free
survival was calculated from diagnosis to the time of first detection
of new lesions or progression of residual lesions. Toxicity was
graded according to the National Cancer Institute Common
Toxicity Criteria (CTC) modified by Seegenschmiedt (1998).
RESULTS
Patient characteristics
From July 1, 1999 to December 31, 2001, a total of 37 patients (10
females, 27 males) aged from 41–77 years (median, 62 years) were
referred from the surgeons with locally advanced rectal cancer
without distant metastasis to our department. All these patients,
fulfilling the including criteria, without any selection were enrolled
in the study. The main reason for the referral of this patients was
an inquestionable R0 resection without preoperative treatment,
because of great tumour mass in the pelvis – the median
longitudinal extension of the tumour based on endorectal
ultrasound was 6cm (range 3–13) – or the infiltration of other
organs. In two cases the main reason was a potentially shincter
preservation by tumours located in the lower third of the rectum
(0–3cm, and 1–3cm from the anal verge). The patient
characteristics are shown in Table 1. Most tumours were located
in the lower third of the rectum (22 patients); in 13 patients the
tumour affected the middle third (5.5–10cm from the anal verge)
and in two patients the upper third of the rectum (410cm from
the anal verge).
Feasibility and toxicity
Six doses of irinotecan were given once weekly as planned in 25
(68%) of all 37 patients. One and two doses of irinotecan had to be
omitted in nine (24%) and three (8%) patients, respectively, in
three cases because of leukopenia grade 3 and 4, in three cases
because of fever, and in six cases because of diarrhoea grade 3 and
4. Acute cholinergic symptoms including acute diarrhoea were not
encountered, and premedication with atropin was not required.
Thromboembolic events were also not seen. Haematologic toxicity
was moderate. Thrombocytopenia grade 3 occurred in one patient
(2%), and leukopenia grade 3 and 4 in three (8%) and one (2%)
patient, respectively. Anaemia grade 3/4 was not observed.
Haemoglobin fell from a median baseline value of 13.2gdl
 1
(range 10.1–16.7) to a median nadir of 11.6gdl
 1 (range 9.2–15.2)
during treatment and reincreased to 12.2gdl
 1 (range 9.7–15.8) at
completion of chemoradiotherapy. The predominant nonhaema-
tologic toxicity was delayed diarrhoea that reached grade 3 in 10
patients (27%) and grade 4 in two patients (5%). Patients with
grade 4 diarrhoea were hospitalised and received parenteral
nutrition. One patient developed an extrapontine myelinolysis
due to severe electrolyte imbalance 2 weeks after completion of
therapy; she received appropriate treatment and recovered without
sequelae. Three patients (8%) developed fever that could be easily
controlled with usual antibiotics. Oral mucositis was not observed,
and also no nausea and vomiting grade 2 and higher, because all
Table 1 Baseline patient characteristics
Patients (N¼37)
Variable No. %
Gender
Male 27 73
Female 10 27
Age (years)
Median 62
Range 41–77
T stage
uT2 2 5
uT3 19 51
uT4 16 43
N stage
uN0 6 16
uN+ 31 84
Tumour localisation (cm from anal verge)
0–5 22 59
5.5–10 13 35
410 2 5
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spatients received before each application of irinotecan dexametha-
sone 8mg and ondansetron 8mg in a prophylactic way. Abdominal
pain, as one criteria in the definition of the grade of diarrhoea in
the CTC, was observed in seven patients. Overall, intensified
chemoradiotherapy was very well tolerated. Minor complications
included transient bladder dysfunction and urinary retention in
two patients that resolved completely without any therapy,
however, within 2–3 weeks after surgery as a typical side effect
of surgery. There were two anastomotic strictures without any
symptoms stumbled on 3 months after primary surgery, which
required dilatation prior to ileostomy closure. In addition,
anastomotic leakage that was amenable to conservative treatment
occurred in two patients, and one perianal wound infection with
subsequent secondary healing.
In one patient chemoradiotherapy had to be discontinued after
40Gy for signs and symptoms of an acute abdomen. A stenosis of
the small intestine was detected in the radiation field in this
patient; he underwent surgery during the acute phase, and
subsequent reoperation was necessary due to an anastomotic leak.
Resectability and type of surgery
Of the 37 patients, 36 proceeded to surgery after completion of
neoadjuvant chemoradiotherapy. One patient refused surgery
because an exploratory biopsy had shown no evidence of residual
tumour. An R0 resection was possible in 32 (89%) of the 36
patients undergoing surgery; the four (11%) remaining patients
had an R1 resection. Sphincter preservation could be achieved in
23 (64%) of 36 patients, while a radical resection of the rectum was
required in 13 (36%) patients. Table 2 shows the surgical approach
by tumour height. So sphincter-saving surgery was possible in 10
of 22 patients (45%) with a tumour less or 5cm from the anal
verge, and in 21 of 34 patients (61%) with a tumour less or 10cm
from the anal verge.
Pathologic response and downstaging
Histologic examination of the resection specimens demonstrated a
pCR of the primary tumour in eight of 36 patients (22%). The
inclusion of the patient who had only an exploratory biopsy
increased the pCR rate to 24% (nine out of 37). In all, 10 patients
(28%) had only microscopic residual disease (MRD), and 14
patients (39%) had a tumour regression by more than 50%,
resulting in a pathologic partial response rate of 67%. A minor
response was achieved in four (11%) patients. No patient failed to
respond. Tumour downstaging by at least one T category was
achieved in 28 (76%) of all 37 patients (Table 3). The pathologic
lymph node status at the time of surgery was pN0 in 25 of 36
patients (69%), pN1 in five patients (14%), and pN2 in six patients
(17%).
Disease control and survival
At a median follow-up of 40 months (range 28–53), 10 of 37
patients had died, of which eight succumbed to their disease. One
patient died after 5 months of pulmonary embolism and another
one after 2 years of congestive heart failure. The estimated local
relapse rate (7standard deviation) at 4 years was 775%. One
patient developed an isolated local recurrence, and another patient
had synchronous local recurrence and liver metastasis. The rate of
distant metastasis at 4 years was 2477%. Among patients with R0
resection, the rate of distant metastasis was 1476.3%. The
actuarial progression-free and overall survivals at 4 years were
7377.6 and 6678.6%, respectively, the disease-specific overall
survival at 4 years was 7078.7%.
Among postoperative disease variables, the resection (R) and
nodal (N) status and the pathohistological response rate were
found to be the most important prognostic determinants. Overall
survival at 4 years was 8177.1% among patients with an R0
resection compared with 0% among those who had an R1 resection
(P¼0.013). Disease-specific survival rates at 4 years were 8476
and 0% for the R0 and R1 patient subgroups, respectively
(P¼0.0001). Patients with no pathologic evidence of lymph node
involvement (pN0) after neoadjuvant chemoradiotherapy had a
4-year progression-free survival of 9276.1% (Figure 1) compared
with 80717.9% for patients with pN1 and 0% for those with pN2
(Po0.0001). Overall survival at 4 years was 80% among patients
with pN0 or pN1 status compared with 33% among patients with
pN2 (P¼0.01). The progression-free survival at 4 years for
patients with complete responses or only MRD was 8878%
(Figure 2) and for patients with only partial response 58712%
(P¼0.06).
DISCUSSION
The primary aim of treatment for rectal cancer is to achieve
complete resection of the tumour and, in the long term, a high
local control and low distant failure rate. An additional aim in low
Table 2 Surgical approach by tumour height
Surgical approach (No. of patients)
Tumour height (cm) Sphincter-saving Radical Total
0–5 10 12 22
5.5–10 11 1 12
410 2 0 2
Table 3 Pathologic downstaging of the primary tumour
Pathologic T stage at the time of surgery (patients)
Clinical T stage
at baseline pT0 pT1 pT2 pT3 pT4 Total
cT2 1 0 0 1 0 2
cT3 4 1 7 7 0 19
cT4 4 0 2 9 1 16
Total 9 1 9 17 1 37
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Figure 1 Progression-free survival by nodal status: pN0, 25 patients (4-
year PFS 9276.1%); pN1, five patients (4-year PFS 80717.9%); pN2, six
patients (4-year PFS 0%). Po0.0001.
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srectal tumours is sphincter preservation. These objectives are
difficult to meet in advanced stages of the disease, and treatment
outcome often remains unsatisfactory in this setting. To improve
the prognosis compared with surgery alone, neoadjuvant 5-
fluorouracil-based chemoradiotherapy has been introduced, with
5-fluorouracil given as a bolus or continuous infusion, with or
without folinic acid. Although these studies reported high rates of
R0 resection, pCR, and sphincter saving, even in low tumours,
many patients eventually developed local or, more common,
distant recurrences. Intensification of neoadjuvant therapy appears
a promising approach to eradicate potential micrometastases more
effectively prior to surgery. Since new agents have improved
treatment results in the palliative setting, several phase II studies
have recently been initiated to examine the usefulness of these
agents given concurrently with radiotherapy as neoadjuvant
treatment. The most promising of these agents are oxaliplatin
and irinotecan. We added irinotecan to 5-fluorouracil in our study
for two reasons: Owing to its high activity in advanced colorectal
cancer (Douillard et al, 2000; Saltz et al, 2000) irinotecan appears
particularly suited for intensified induction therapy; in addition,
several studies have documented the radiosensitising properties of
irinotecan (Boothmann et al, 1987; Boscia et al, 1993; Omura et al,
1997; Chen et al, 1999) that were observed even under hypoxic
conditions (Boscia et al, 1993). As hypoxia may have an adverse
effect on the radiosensitivity of cells (Kumar, 2000; Fyles et al,
2000), irinotecan may be particularly useful as a constituent of
chemoradiotherapy programmes in patients with bulky pelvic
tumours and poor blood supply that often contain hypoxic
regions.
The R0 resection rate of 89% in our study is in the upper range
of results reported for neoadjuvant chemoradiotherapy in locally
advanced rectal cancer with 5-fluorouracil alone. Moreover, our
long-term local control rate of 93% at 4 years is comparable to the
results achieved with concurrent 5-fluorouracil and radiation in
the study of the German Rectal Cancer Group (Sauer et al, 2004),
even though patients in this study had on average less advanced
disease. Sphincter-saving surgery was possible in our study in as
many as 10 (45%) out of 22 patients with very low rectal cancers
(p5cm from anal verge), most of which would have required total
resection if no neoadjuvant treatment had been given. One of these
10 patients developed after 15 months distant metastasis in the
liver and a locoregional recurrence, and died after 39 months with
normal sphincter function.
The intensified neoadjuvant multi-modality programme with 5-
fluorouracil, irinotecan, and concurrent radiation that we used in
our study shows a higher rate of diarrhoea compared with studies
using only 5-fluorouracil in different ways. So, in schemes with
only 5-fluorouracil, the rate of grade 3
4 diarrhoea is about 20–25%;
adding irinotecan, the rate of grade 3
4 diarrhea is about 30–40%. In
our study the rate of grade 3
4 diarrhoea was 32% and this is in
keeping with the findings in other studies using this combination
(Mitchell et al, 2001; Mehta et al, 2003). Therefore, this intensified
neoadjuvant scheme with 5-fluorouracil, irinotecan, and concur-
rent radiation must include an intensified care and supportive
treatment for the patients. Then this scheme is safe and effective.
Since both 5-fluorouracil and pelvic radiation cause diarrhoea as
an adverse effect, irinotecan cannot be administered at weekly
doses of 80–100mgm
 2 that are usually given in combination
with 5-fluorouracil and folinic acid without radiation therapy
(Douillard et al, 2000; Saltz et al, 2000). We chose an irinotecan
dose of 40mgm
 2, while 50mgm
 2 was used in the other
published studies, though in combination with a lower daily dose
of 5-fluorouracil (225mgm
 2) compared with our regimen
(250mgm
 2). The total doses of irinotecan were 200 and
250mgm
 2 in the other studies (Mitchell et al, 2001; Mehta
et al, 2003) and 240mgm
 2 in the present trial. Diarrhoea was also
a predominant nonhaematologic toxicity seen with other chemor-
adiation protocols (Table 4). Nevertheless, adding irinotecan to
radiation and 5-fluorouracil the rate of diarrhoea is higher, but this
acute toxicity is manageable with an intensified care and if needed
with supportive treatment.
The effectivity of neoadjuvant therapy of rectal cancer is usually
measured by the rate of pathologically confirmed complete
responses (pCR). A pCR rate of 8–10% was found in studies with
5-fluorouracil-based regimens, 5% in an earlier study of our group
(Ku ¨chenmeister et al, 2000) and the substitution of an oral
prodrug for intravenous 5-fluorouracil does not appear to improve
these results, with a pCR rate of 4–9% (Table 4) besides one
exception by a group from Korea with a pCR rate of 31% (Kim
et al, 2002). Compared with these data, the addition of irinotecan
to 5-fluorouracil in the present study resulted in a gross doubling
of the pCR rate to over 20%. These favourable results are in line
with those recently reported for the 5-fluorouracil–irinotecan
combination by Mehta et al (2003) and Mitchell et al (2001), who
achieved a pCR rate of 37% in 32 patients with T3 tumours, and of
24% in a patient population which included a few T4 tumours,
respectively (Table 4). More recently, pCR rates from 12 to 21%
were reported for the combination of oxaliplatin with 5-fluoro-
uracil or 5-fluorouracil prodrugs.
In the preoperative treatment of other gastrointestinal cancers,
like gastric cancer or oesophageal cancer, the rate of pCR is an
independent factor for survival (Forastiere et al, 1997; De Vita
et al, 2002; Terrosu et al, 2003; Ajani et al, 2004). Also, in our
study, the progression-free survival for patients with complete
responses or only MRD is higher than for patients with only partial
response (4-year OS: 8878 vs 58712%; P¼0.06; see Figure 2).
Unfortunately, most studies of intensified neoadjuvant chemo-
radiotherapy did not report long-term results with regard to local
control, late toxicities or, most importantly, the probability of
distant metastasis. We have therefore evaluated our data after a
long median follow-up of 36 months, with a minimum follow-up of
24 months for surviving patients. In randomised trials, well over
30% of the patients with stage II or III rectal cancer developed
distant dissemination. However, neoadjuvant chemoradiation
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Figure 2 Progression-free survival by response status: pCR, MRD: 18
patients (4-year PFS 8878%); pPR, pNC 18 patients (4-year PFS
58712%); P¼0.06.
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sregimens including 5-fluorouracil alone have failed to prevent
tumour spread to distant organs. The size of the problem related to
distant metastasis in locally advanced rectal cancer becomes even
more evident if one considers not only selected study populations
but also consecutive patient series in everyday practice. In a
retrospective analysis of patients who received adjuvant chemo-
radiotherapy with 5-fluorouracil and folinic acid at the University
of Wu ¨rzburg, Germany, distant failures occurred in as much as
49% of stage III patients (Bagatzounis et al, 2000). Although the
patients in our phase II study had comparatively large, advanced
tumours, only 24% developed distant metastasis, and among those
with R0 resection the rate was as low as 14%. Taking also into
account the extended follow-up, these results possibly suggest an
improved systemic effect of our intensified neoadjuvant treatment
regimen compared with the other adjuvant or neoadjuvant
protocols reported so far. Of course these data has to be proven
in phase III trials comparing neoadjuvant 5-fluorouracil-based
treatment with intensified schemes with oxaliplatin or irinotecan.
Another interesting, though preliminary, finding of our study
was the outstanding prognostic significance of postoperative nodal
status. While pN0 and pN1 patients had progression-free survivals
at 4 years of 92 and 80%, respectively, all pN2 patients had a
recurrence, usually at a distant site, within the first 2 years
(Figure 1). It is likely therefore that the former group of patients
will not benefit from further intensification of treatment. In
contrast, additional postoperative therapy, perhaps in the form of
maintenance chemotherapy, should be strongly considered in pN2
patients.
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